The tragedy that is Trasylol and the scores of people who have died at the hands of the expensive anti-bleeding drug reads like the plot line of a bad movie. Only in this case, the villain doesn't get it in the end. At least, not yet. That payback may eventually be found in the courts of law as hundreds of lawsuits move forward...
If there is a lesson that could be taken from the Trasylol tragedy, it might be that drug makers who hide, avoid, or mistakenly withhold important safety data from public, or even medical consumption would face certain censure in some fashion as an inducement not to ever allow such an oversight to happen again...
If there is a lesson that could be taken from the Trasylol tragedy, it might be that drug makers who hide, avoid, or mistakenly withhold important safety data from public, or even medical consumption would face certain censure in some fashion as an inducement not to ever allow such an oversight to happen again...
In what is fast becoming a never-ending story, a drug that showed no concern in clinical trials is suddenly under the microscope now that the drug is on the market and used by a wider number of Americans. This time it's HIV drugs Ziagen, and Videx, two drugs that have now been identified as posing a greater risk for heart attack than other HIV medications...
